Heywood James, Evangelou Marina, Goymer Donna, Kennet Jane, Anselmiova Katerina, Guy Catherine, O'Brien Criona, Nutland Sarah, Brown Judy, Walker Neil M, Todd John A, Waldron-Lynch Frank
JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cambridge Institute for Medical Research, University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, CB2 0XY, UK.
The Cambridge BioResource, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
Trials. 2015 Mar 11;16:86. doi: 10.1186/s13063-015-0583-7.
A barrier to the successful development of new disease treatments is the timely recruitment of participants to experimental medicine studies that are primarily designed to investigate biological mechanisms rather than evaluate clinical efficacy. The aim of this study was to analyse the performance of three recruitment sources and the effect of publicity events during the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).
The final study outcome, demography, disease duration, residence and the effect of publicity events on the performance of three recruitment sources (clinics, type 1 diabetes (T1D) disease register and the internet) were analysed from a bespoke DILT1D recruitment database. For the internet source, the origin of website hits in relation to publicity events was also evaluated.
A total of 735 potentially eligible participants were approached to identify the final 45 DILT1D participants. A total of 477 (64%) were identified via the disease register, but only 59 (12%) responded to contact. A total of 317 individuals registered with the DILT1D study team. Self-referral via the study website generated 170 (54%) registered individuals and was the most popular and successful source, with 88 (28%) sourced from diabetes clinics and 59 (19%) from the disease register. Of those with known T1D duration (N = 272), the internet and clinics sources identified a larger number (57, 21%) of newly diagnosed T1D (<100 days post-diagnosis) compared to the register (1, 0.4%). The internet extended the geographical reach of the study, enabling both national and international participation. Targeted website posts and promotional events from organisations supporting T1D research and treatment during the trial were essential to the success of the internet recruitment strategy.
Analysis of the DILT1D study recruitment outcomes illustrates the utility of an active internet recruitment strategy, supported by patient groups and charities, funding agencies and sponsors, in successfully conducting an early phase study in T1D. This recruitment strategy should now be evaluated in late-stage trials to develop treatments for T1D and other diseases.
NCT01827735 (registered: 4 April 2013); ISRCTN27852285 (registered: 23 March 2013); DRN767 (registered: 21 January 2013).
新疾病治疗方法成功研发的一个障碍是能否及时招募参与者参与主要旨在研究生物学机制而非评估临床疗效的实验性医学研究。本研究的目的是分析在1型糖尿病白细胞介素-2剂量对调节性T细胞的适应性研究(DILT1D)中三种招募来源的表现以及宣传活动的效果。
从一个定制的DILT1D招募数据库中分析最终研究结果、人口统计学、病程、居住地以及宣传活动对三种招募来源(诊所、1型糖尿病(T1D)疾病登记册和互联网)表现的影响。对于互联网来源,还评估了与宣传活动相关的网站点击来源。
共联系了735名潜在符合条件的参与者以确定最终的45名DILT1D参与者。通过疾病登记册确定了477名(64%),但只有59名(12%)回复了联系。共有317人向DILT1D研究团队登记。通过研究网站自荐产生了170名(5